Fulgent Genetics (FLGT) Q1 2026 earnings review
Transition Pain: Customer Loss Crushes Margins Despite M&A Offset
Fulgent's Q1 2026 results confirm the severe financial impact of losing its largest customer. Revenue is decelerating, dropping to $71.1 million, but the real story is the collapsing bottom line. Operating leverage vanished, driving Non-GAAP gross margins down to 32.3% and Adjusted EBITDA reversing sharply to a $15.2 million loss. Despite the margin destruction, management maintained its $350 million full-year revenue guidance, heavily relying on the newly closed Bako and StrataDx acquisitions to backfill the gap. Massive stock repurchases ($48.7 million) further drained cash, forcing a downward revision to both EPS and year-end cash guidance.
🐂 Bull Case
The acquisitions of Bako Diagnostics and StrataDx have officially closed. This adds critical scale in anatomic and dermatopathology, directly addressing the revenue void left by the major customer departure.
Management continues to aggressively buy back stock at depressed valuations, retiring 3.1 million shares for $48.7 million in Q1 alone, signaling high confidence in long-term cash generation.
🐻 Bear Case
The loss of high-volume legacy testing destroyed gross margins, which plummeted nearly 900 basis points sequentially to 32.3%. The path to historical ~40%+ margins relies entirely on flawless integration of the new acquisitions.
Adjusted EBITDA swung to a heavy loss, and a delayed $106 million IRS tax refund is compounding liquidity pressure. The year-end cash forecast was slashed by nearly $50 million.
⚖️ Verdict: 🔴
Bearish. While the $350M revenue guidance holds steady thanks to M&A, the quality of earnings has deteriorated violently. Until the gross margin normalizes and the heavy cash burn slows, the fundamental transition remains highly risky.
Key Themes
Data Contradicts Management's 'Positive Trajectory' Claim
CEO Ming Hsieh stated he is 'encouraged by our first quarter performance and the positive trajectory,' but the financials show profitability is reversing sharply. Non-GAAP operating margin cratered to -27.7% (down from -10.7% in 25Q4), and Adjusted EBITDA fell to a $15.2M loss. The departure of their largest customer (historically ~22% of revenue) has completely decoupled fixed costs from volume, resulting in a severe profit contraction that contradicts the optimistic tone.
Macro Impact: Government Shutdown Delays Vital Tax Refund
Macroeconomic friction is actively hindering Fulgent's balance sheet. A critical $106 million tax refund remains delayed due to the government shutdown in late 2025 and ongoing constrained resources at the IRS. This liquidity bottleneck forces Fulgent to fund its heavy M&A and buyback programs from existing reserves, pushing its projected year-end cash balance down to $636 million.
Bako and StrataDx Integration Closes
The foundational driver for H2 revenue recovery is now in place, with the acquisitions of Bako Diagnostics and StrataDx officially complete. Management is relying on these anatomic pathology assets to contribute an estimated $50M-$55M annually, diversifying the client base and replacing the legacy revenue gap. Execution here is mandatory to hit the maintained $350M full-year revenue target.
Therapeutic Pipeline Innovations Gaining Validation
Fulgent's pivot from pure diagnostics to a precision medicine developer is accelerating. Its lead candidate, FID-007 (utilizing a proprietary nanoencapsulation drug delivery platform for head and neck cancer), was selected for a rapid oral abstract at the 2026 ASCO Annual Meeting. This clinical validation of Phase 2 data is a crucial milestone for the company's long-term valuation shift.
Digital Pathology to Drive H2 Margin Recovery
Management expects gross margins to 'normalize and further improve in the second half of the year.' This driver depends on leveraging their fully transitioned EZOPAS digital pathology platform. By utilizing AI modules and remote reading networks, the company aims to scale the newly acquired Bako and StrataDx case volumes without a linear increase in expensive pathologist headcount.
Aggressive Buybacks Punishing EPS Metrics
The company allocated $48.7 million to repurchase 3.1 million shares in Q1. Because Fulgent is operating at a net loss, reducing the share count mechanically worsens the per-share loss metrics. Consequently, management was forced to lower its full-year Non-GAAP EPS guidance to $(1.59), highlighting the optics risk of aggressive buybacks during a profit trough.
Other KPIs
Reversing sharply from 41.0% in 25Q4. This ~870 bps sequential compression illustrates the massive deleveraging impact of losing high-margin, high-volume testing from their legacy top customer. Margin recovery in H2 is entirely dependent on successfully absorbing and scaling the newly acquired diagnostic labs.
Decelerating violently from a -$4.5 million loss in 25Q4 and near breakeven in prior quarters. The surge in losses stems directly from maintaining high R&D and SG&A infrastructure costs against a significantly reduced core revenue base.
Down heavily from $705.5 million at the end of 2025. The rapid sequential drain was driven by $48.7 million in stock buybacks, elevated operational cash burn, and ongoing capital expenditures.
Guidance
Stable. The company maintained its full-year target despite a weak $71.1M in Q1. This implies accelerating growth in Q2-Q4, requiring an average of ~$93 million per quarter to hit the target. This heavily relies on Bako and StrataDx coming online immediately.
Decelerating. Worsened from previous expectations of $(1.45). Driven by the combined impact of higher-than-expected Q1 margin compression and the mechanical impact of a reduced outstanding share count following aggressive stock buybacks.
Decelerating trajectory. The year-end cash target was revised downward (previously expected up to $685M) to account for the $48.7 million used in the stock repurchase program. This assumes the delayed $106 million IRS tax refund arrives before December 31, 2026.
Key Questions
Margin Normalization Bridge
You guided for gross margins to normalize in the second half of the year. Given the steep drop to 32.3% this quarter, how much of this expected recovery is driven by organic cost-cutting versus higher-margin contribution from Bako and StrataDx?
Capital Allocation Priorities
With Adjusted EBITDA losses widening to $15.2 million and the IRS tax refund still delayed, is it prudent to continue aggressively retiring stock ($48.7M in Q1), or will you pause buybacks to preserve the balance sheet until the core business stabilizes?
Therapeutic Commercialization
As FID-007 prepares for a rapid oral abstract at ASCO, what are the next strategic steps? Are you looking to partner the asset to offset the $26 million annual therapeutic cash burn, or do you intend to fund Phase 3 trials independently?